ZNF671

Across TCGA pan-cancer cohorts, ZNF671 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated ZNF671 data layer compared with 19 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher ZNF671 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ZNF671 expression acts as an unfavorable survival marker, although some lineages such as LUSC show a favorable association.

OV, LUAD, and PRAD are the cancer types where ZNF671 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	III,IV	0.028	0.837	<.001	24	view →
LUAD	OS	Median	III,IV	0.057	0.680	<.001	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LGG	DFS	Median	All	0.249	0.728	.038	3	view →
LUSC	DFS	Median	All	1.000	0.387	.043	3	view →
COAD	DFS	Median	II,III,IV	0.196	0.687	.012	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

ZNF671–OV (OS)

Open the OV breakdown →